Myfembree denied as non-formulary by Cigna?

Cigna's specific coverage criteria for myfembree are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Myfembree as Non-Formulary — and Your Appeal Options

A non-formulary denial means Myfembree (relugolix, estradiol, and norethindrone acetate) is not included on Cigna's preferred drug list for your specific plan, or is placed at a tier that makes it cost-prohibitive or subject to additional coverage criteria. Non-formulary status does not mean the drug is excluded from coverage — it means you need to either pursue a formulary exception or demonstrate that the formulary alternatives are not clinically appropriate for your situation. Formulary exception appeals succeed regularly when a prescriber documents why no covered alternative is adequate.

## The Federal Appeal Framework

• Formulary exception request: This is a separate process from a standard appeal, though Cigna must treat it with the same procedural rights. Submit a formulary exception request with a physician letter explaining why the non-formulary drug is medically necessary and why formulary alternatives are not appropriate for this patient.
• Internal appeal (Level 1): If the exception request is denied, file a formal internal appeal within Cigna's deadline (typically 180 days). Cigna must respond within 30 days for pre-service non-urgent requests or 72 hours for expedited reviews.
• External review (ACA §2719): After a final internal denial, request independent external review — generally within 4 months. The IRO applies clinical standards; formulary decisions overriding medical necessity are frequently reversed on external review.
• ERISA §503: Employer plan members are entitled to specific clinical reasoning for a denied exception, not just a formulary tier citation.

## Documents to Gather

1. List of formulary alternatives Cigna identified: Obtain from Cigna or your pharmacy the specific covered drugs Cigna considers therapeutically equivalent. Your physician must address each one by name. 2. Prescriber comparison letter: For each formulary alternative, your physician should document either (a) that the patient already tried it and it was inadequate or not tolerated, with dates and outcomes; or (b) a clinical reason it is contraindicated or otherwise inappropriate for this patient. Refer to the FDA-approved prescribing information for Myfembree to identify its specific approved indication and formulation. 3. Diagnosis and severity documentation: Records confirming the diagnosis (endometriosis-associated pain or fibroid-related heavy menstrual bleeding) and clinical severity. 4. Prior therapy history: A timeline of all hormonal or other therapies already tried, with outcomes — particularly relevant if Cigna's formulary alternatives were among those already attempted. 5. Cigna's formulary exception criteria: Obtain the specific criteria Cigna requires for a non-formulary exception and ensure the physician letter directly addresses each one.

## Criteria-Mapping Structure

In the exception request and appeal letter:

• List each formulary alternative Cigna identified.
• For each: state whether it was tried (with outcome and dates) or explain the clinical basis for why it is not appropriate for this patient.
• State affirmatively that Myfembree is within its FDA-approved indication for this patient's confirmed diagnosis.
• Close with the treating physician's clinical judgment that no formulary alternative provides equivalent therapeutic benefit for this patient.

Formulary exceptions are a routine, well-established process — a well-documented physician letter is often sufficient to secure approval at the exception stage without needing to advance to external review.